Clues to Breast Cancer Hidden Inside Stem Cells
News Apr 25, 2006
Scientists from the Icelandic Cancer Society and the Faculty of Medicine, University of Iceland have grown three-dimensional breast cell cultures to reveal unexpected subtleties about stem cells that could explain why they spawn malignancies.
These stem cells, Valgardur Sigurdsson remarked during the EuroSTELLS Conference in Venice, Italy (19-21 March), could become targets for cancer treatment, leading to new therapies that wipe out cancer at its source.
"People have long suspected there should be a stem cell population in the human breast gland," said Sigurdsson who is part of the ESF-funded team led by Thorarinn Gudjonsson.
A 'virgin' breast, before pregnancy, is very different to a fully functioning, milk-producing breast. With lactation, the breast becomes fully differentiated, and once this stage is over, it involutes.
This cycle of proliferation, differentiation and apoptosis also happens in every menstrual cycle and in a more dramatic form during pregnancy.
"This caught our attention, and has driven our research," Sigurdsson pointed out.
In 2002, Thorarinn Gudjonsson has isolated cells from the human breast with stem cell properties.
Gudjonsson immortalised these cells and grew them in three dimensional matrix that mimics the real, living tissue. Biologists have long relied on 2-dimensional cell cultures as the basic tool of their trade.
But there is a big difference between a flat layer of cells and culturing cells in three-dimensions.
The Icelandic researchers, realising just how much a cells context matters, used the 3-D cell culture pioneered by Mina Bissell, at the Lawrence Berkeley National Laboratory in California.
"We can build up a 3-D breast structure similar to what you have in vivo," says Gudjonsson.
"You can analyse cell-cell interactions and signalling pathways in these cells during morphogenesis and in cancer progression."
The Icelandic researchers are now focusing their efforts on how endothelial cells convey signals to stem cells in normal breast formation and in cancer.
In collaboration with another Icelandic research team, the Gudjonsson lab is now unravelling the role of tyrosine kinase receptors and their downstream signalling events. The benefits of these 3-D assays are manifold.
"This is a useful system for drug screening and testing new drugs as well as for understanding cancer progression," says Gudjonsson.
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019